A strategy of an upfront TKI to reduce the burden of CNS disease and avoid WBRT, potentially followed by SRS, termed “CNS downstaging”, has also being examined as a strategy for EGFR-, ALK-, or ROS1-driven NSCLC patients with extensive BrMs (>10) at presentation [146]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.